Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)

被引：0
|
作者：
Zhang, Tian
Staats, Janet S.
Chan, Cliburn
Harrison, Michael Roger
O'Donnell, Peter H.
Batich, Kristen A.
Chen, Tianling
Krejsa, Cecile
Izumi, Raquel
George, Daniel J.
Weinhold, Kent J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
[3] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA
[4] ICON Dev Soult, Palo Alto, CA USA
[5] Acerta Pharma, Redwood City, CA USA
[6] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4533
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial
    Harrington, K.
    Machiels, J. -P.
    Shin, S. W.
    Cohen, E.
    Burtness, B.
    Gause, C.
    Swift, A.
    Swaby, R.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 5 - 6
  • [32] KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.
    Bellmunt, Joaquim
    Sonpavde, Guru
    De Wit, Ronald
    Choueiri, Toni K.
    Siefker-Radtke, Arlene O.
    Plimack, Elizabeth R.
    Lewis, Nicole M.
    Brown, Holly
    Mai, Yabing
    Gause, Christine K.
    Kaufman, David Ross
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).
    Batich, Kristen A.
    Staats, Janet S.
    Chan, Cliburn
    Krejsa, Cecile
    George, Daniel J.
    Weinhold, Kent J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
    INOUE, S. A. T. O. S. H. I.
    SASSA, N. A. O. T. O.
    KAWANISHI, H. I. D. E. J. I.
    YUGUCHI, Y. U. R. I.
    SUZUKI, T. O. M. O. H. I. D. E.
    NAGAYAMA, J. U. N.
    MATSUI, H. I. R. O. T. A. K. A.
    MIYATA, Y. U. D. A. I.
    SOEDA, Y. U. Y. A.
    TOCHIGI, K. O. S. U. K. E.
    YAMAUCHI, Y. U. S. H. I.
    MAEDA, M. O. T. O. H. I. R. O.
    KOBAYASHI, I. K. U. O.
    HATTORI, R. Y. O. H. E. I.
    MATSUKAWA, Y. O. S. H. I. H. I. S. A.
    KATO, M. A. S. A. S. H., I
    ANTICANCER RESEARCH, 2022, 42 (07) : 3627 - 3636
  • [35] Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.
    Yuan, Yuan
    Ge, Xuan
    Yost, Susan Elaine
    Lee, Jin Sun
    Frankel, Paul Henry
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Mortimer, Joanne E.
    Waisman, James Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
    Kawazoe, Akihito
    Kuboki, Yasutoshi
    Shinozaki, Eiji
    Hara, Hiroki
    Nishina, Tomohiro
    Komatsu, Yoshito
    Yuki, Satoshi
    Wakabayashi, Masashi
    Nomura, Shogo
    Sato, Akihiro
    Kuwata, Takeshi
    Kawazu, Masahito
    Mano, Hiroyuki
    Togashi, Yosuke
    Nishikawa, Hiroyoshi
    Yoshino, Takayuki
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5887 - 5894
  • [37] Presence of constipation predicts the therapeutic efficacy of pembrolizumab in metastatic urothelial cancer patients
    Inoue, Satoshi
    Sassa, Naoto
    Kato, Takashi
    Yamauchi, Yushi
    Hirabayashi, Tsuyoki
    Yuguchi, Yuri
    Maeda, Motohiro
    Soeda, Yuya
    Hattori, Ryohei
    Gotoh, Momokazu
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (12) : 1116 - 1123
  • [38] Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
    Tamaskovics, B. F.
    Hecht, M.
    Schubert, P.
    Kallies, A.
    Illmer, T.
    Radke, J.
    Koelbl, O.
    Steger, F.
    Brunner, T. B.
    Roedel, C.
    Fleischmann, M.
    Reinacher-Schick, A.
    Wingender, L. F.
    Melchior, P.
    Klautke, G.
    Hintzen, U.
    Gaipl, U. S.
    Haussmann, J.
    Budach, W.
    Fietkau, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S593 - S593
  • [39] Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer.
    Welsh, James William
    Menon, Hari
    Tang, Chad
    Verma, Vivek
    Altan, Mehmet
    Hess, Kenneth R.
    de Groot, Patricia
    Quynh Nguyen
    Simon, George R.
    Skoulidis, Ferdinandos
    Chang, Joe Y.
    Papadimitrakopoulou, Vassiliki
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
    Welsh, James
    Menon, Hari
    Chen, Dawei
    Verma, Vivek
    Tang, Chad
    Altan, Mehmet
    Hess, Kenneth
    de Groot, Patricia
    Nguyen, Quynh-Nhu
    Varghese, Rejani
    Comeaux, Nathan, I
    Simon, George
    Skoulidis, Ferdinandos
    Chang, Joe Y.
    Papdimitrakopoulou, Vasiliki
    Lin, Steven H.
    Heymach, John, V
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
12345